Antilung cancer effect of WT1-specific cytotoxic T lymphocytes

Clinical Cancer Research

Volumn 8, Issue 8, 2002, Pages 2626-2631

  Makita, Masanori ^a,b   Hiraki, Akio ^b   Azuma, Taichi ^a   Tsuboi, Akihiro ^c   Oka, Yoshihiro ^c   Sugiyama, Haruo ^c   Fujita, Shigeru ^a   Tanimoto, Mitsune ^b   Harada, Mine ^d   Yasukawa, Masaki ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A2 ANTIGEN; HLA A24 ANTIGEN; HLA ANTIGEN CLASS 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG; WT1 PEPTIDE; ANTINEOPLASTIC AGENT; MESSENGER RNA; PEPTIDE; WT1 PROTEIN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL CLONE; CELL GROWTH; CELL SPECIFICITY; CELL STRAIN TAK 1; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; SOLID TUMOR; TARGET CELL; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CD8+ T LYMPHOCYTE; CELL CULTURE; CHEMISTRY; IMMUNOTHERAPY; LUNG TUMOR; METABOLISM; METHODOLOGY; NUDE MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME;

ANIMAL; ANTINEOPLASTIC AGENTS; CD8-POSITIVE T-LYMPHOCYTES; IMMUNOTHERAPY; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PEPTIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SUPPORT, NON-U.S. GOV'T; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; TUMOR CELLS, CULTURED; WT1 PROTEINS; ANIMALS;

EID: 0036023425     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus
2. The WT1 Wilms' tumor gene product: A developmentally regulated transcription factor in the kidney that functions as a tumor suppressor
3. The candidate Wilms' tumor gene is involved in genitourinary development
4. Tissue, developmental, and tumor-specific expression of divergent transcripts in Wilms tumor
5. The Wilms' tumor gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma
6. Expression of the Wilms' tumor gene WT1 in the murine urogenital system
7. Expression of the Wilms' tumor gene (WT1) in human leukemias
8. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia
9. The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells
10. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias
11. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth
12. Wilms' tumor gene (WT1) expression in lung cancer, colon cancer and glioblastoma cell lines compared to freshly isolated tumor speciemens
13. + cytotoxic T-lymphocyte clone specific for WT1 peptide
14. Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes
15. Sequence-based association analysis of HLA class I and II alleles in Japanese supports conservation of common haplotypes
16. + T lymphocytes
17. + T cells
18. + human cytotoxic T cell clones directed against herpes simplex virus
19. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1
20. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product
21. WT-1 is required for early kidney development
22. Cancer immunotherapy targeting Wilms' tumor gene WT1 product
23. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
24. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
25. Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells
26. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
27. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes
28. Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination